Ionis Pharmaceuticals (NASDAQ:IONS) Shares Down 7.3% on Analyst Downgrade

Key Points

• Ionis shares fell 7.3% to about $28.75 after Needham cut its price target from $86 to $54, while maintaining a Buy rating.
• Ionis reported Q3 revenue of $242.7 million, up about 55% year over year and above estimates, and a narrower-than-expected loss. However, it cut its 2026 TRYNGOLZA sales outlook to about $50 million from $100 million–$110 million, citing slower uptake and competition.
• Other analysts also lowered targets, though Needham and HC Wainwright kept Buy ratings. MarketBeat cited a consensus rating of Moderate Buy and an average price target of $84.62.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report)'s stock price traded down 7.3% on Tuesday after Needham & Company LLC lowered their price target on the stock from $86.00 to $54.00. Needham & Company LLC currently has a buy rating on the stock. Ionis Pharmaceuticals traded as low as $29.21 and last traded at $28.7480. Approximately 978,814 shares traded hands during trading, a decline of 64% from the average daily volume of 2,736,926 shares. The stock had previously closed at $31.00.

Several other research firms also recently issued reports on IONS. Bank of America reaffirmed a "buy" rating on shares of Ionis Pharmaceuticals in a research note on Tuesday. UBS Group assumed coverage on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. They set a "buy" rating and a $88.00 price objective for the company. HC Wainwright lowered their target price on shares of Ionis Pharmaceuticals from $100.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday. Wolfe Research lowered shares of Ionis Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research report on Thursday, July 16th. Finally, Wall Street Zen downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 1st. Nineteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $84.62.

Insider Activity

In related news, EVP Shannon Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the transaction, the executive vice president directly owned 17,811 shares of the company's stock, valued at approximately $775,490.94. The trade was a 7.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 1.81% of the company's stock.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose about 55% year over year to $242.7 million, above estimates, and the quarterly loss was narrower than analysts expected. DAWNZERA sales also increased 40% to $37 million. Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue, Cuts TRYNGOLZA Sales Guidance
• Positive Sentiment: HC Wainwright and Needham retained “buy” ratings despite lowering their price targets to $70 and $54, respectively. Both targets remain above the cited current share price. Read More.; Read More.
• Negative Sentiment: Ionis cut its 2026 TRYNGOLZA sales outlook to about $50 million, down from its prior $100 million–$110 million forecast, citing slower uptake and competitive pressures. The disappointing launch outlook overshadowed the earnings beat and prompted a sharp selloff. Ionis: 3 Key Takeaways for Long-Term Investors
• Negative Sentiment: The company’s 2026 revenue guidance of $875 million–$900 million is below the approximately $920.8 million analyst consensus, adding to concerns about the outlook. Ionis Q3 Revenue Rises; Lowers TRYNGOLZA Sales Outlook
• Neutral Sentiment: Law firms announced investigations following the forecast reduction. These notices are not findings of wrongdoing, but may add uncertainty for investors. Investigation Notice

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Edgestream Partners L.P. acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth $807,000. Ground Swell Capital LLC purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at about $547,000. Allworth Financial LP raised its position in shares of Ionis Pharmaceuticals by 79.8% during the 3rd quarter. Allworth Financial LP now owns 928 shares of the company's stock worth $41,000 after purchasing an additional 412 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 33.4% in the third quarter. Fisher Asset Management LLC now owns 182,997 shares of the company's stock worth $8,171,000 after acquiring an additional 45,813 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Ionis Pharmaceuticals by 110.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 170,799 shares of the company's stock valued at $7,773,000 after acquiring an additional 89,480 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors.

Ionis Pharmaceuticals Trading Down 7.3%

The company has a fifty day simple moving average of $46.20 and a 200-day simple moving average of $65.63. The company has a current ratio of 7.89, a quick ratio of 7.73 and a debt-to-equity ratio of 3.07. The company has a market capitalization of $4.78 billion, a PE ratio of -8.39 and a beta of 0.43.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($1.23) by $0.57. The business had revenue of $242.72 million during the quarter, compared to analysts' expectations of $178.17 million. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%. The company's revenue was up 54.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.80) EPS. Analysts predict that Ionis Pharmaceuticals, Inc. will post -3.62 EPS for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company's research and development programs span neurological, cardiovascular, metabolic and rare diseases.

Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.